Bond 1976.

Methods	Randomised Phase II trial
Participants	Number of participants not stated in the paper. Number included in the analysis was 41. Women with histologically confirmed squamous cell carcinoma of the cervix. Most had previously received radical radiotherapy followed by recurrence of local disease, distant metastases or both
Interventions	Arm 1: doxorubicin 50 mg iv, vincristine 2 mg iv, methotrexate 50 mg iv all d1 q28 Arm 2: doxorubicin 50 mg iv, vincristine 2 mg iv, methotrexate 50 mg iv, bleomycin 15 mg iv all d1 q28
Outcomes	Toxicity Response rates Median survival
Notes	Standard doses of drugs given regardless of height, weight or surface area in order to avoid risk of incorrect dose calculation when treatment administered by junior staff. No ITT analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number of participants not stated in the paper. Number included in the analysis was 41
Selective reporting (reporting bias)	Unclear risk	Total number of trial participants not stated only those evaluable
Other bias	Unclear risk	No comparison of patient characteristics between the 2 groups given